Michael F. MacLean - 14 Feb 2023 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Michael MacLean
Issuer symbol
VERV
Transactions as of
14 Feb 2023
Transactions value $
$0
Form type
4
Filing time
16 Feb 2023, 16:00:24 UTC
Previous filing
24 Jan 2023
Next filing
20 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +7K $0.00 7K 14 Feb 2023 Common Stock 7K $21.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. The shares of common stock underlying the option are scheduled to vest in full upon the one-year anniversary of the grant date, subject to the Reporting Person's continued service.